Tapinarof cream, sold under the brand name Vtama, is one of the most promising prescription ointments for plaque psoriasis in years — the first steroid-free topical approved for adults in over a decade. Clinical trials showed it cleared or nearly cleared psoriasis in roughly 40 percent of patients after 12 weeks, and unlike corticosteroids, it carries no risk of skin thinning with long-term use. But the hidden catch is folliculitis, a painful inflammation of hair follicles that affects roughly 20 percent of users and can be severe enough to make people quit treatment altogether. For older adults, particularly those managing cognitive decline or dementia alongside chronic skin conditions, this side effect creates a real dilemma: the ointment works, but the secondary irritation may go unreported or be mistaken for a new skin problem entirely.
This matters more than most dermatologists acknowledge. A person with moderate-to-advanced dementia may not be able to articulate that the burning, red bumps appearing on their skin started after they began a new cream. Caregivers who aren’t briefed on folliculitis as a known side effect might assume an infection and seek unnecessary antibiotics. The disconnect between effective treatment and hidden complications is especially dangerous in populations that already struggle with medication management. This article breaks down how tapinarof works, why folliculitis is so common with it, what caregivers should watch for, and when the tradeoff simply isn’t worth it.
Table of Contents
- Why Does This Prescription Psoriasis Ointment Have a Hidden Catch?
- What Folliculitis Looks Like and Why It Gets Missed in Older Adults
- Managing Psoriasis in People With Dementia — The Bigger Picture
- How Tapinarof Compares to Other Psoriasis Treatments for Older Adults
- Warning Signs Caregivers Should Watch For
- When the Tradeoff Isn’t Worth It
- What’s Ahead for Steroid-Free Psoriasis Treatment
- Conclusion
- Frequently Asked Questions
Why Does This Prescription Psoriasis Ointment Have a Hidden Catch?
Tapinarof is an aryl hydrocarbon receptor agonist, which means it works by activating a specific receptor in skin cells that regulates inflammation and helps restore the skin barrier. Unlike topical steroids such as betamethasone or clobetasol, which suppress the immune response broadly and thin the skin over time, tapinarof targets a narrower pathway. This is genuinely good news for people who need long-term psoriasis management — steroid-induced skin atrophy is a serious concern for elderly patients whose skin is already fragile. In head-to-head comparisons, tapinarof showed durable results even after patients stopped applying it, something steroids almost never achieve. The hidden catch is that the same mechanism encouraging skin cell turnover and barrier repair also appears to irritate hair follicles.
In the pivotal PSOARING trials, folliculitis occurred in about 20 percent of participants using tapinarof, compared to roughly 1 percent in the vehicle-only group. The folliculitis typically shows up as red, sometimes pus-filled bumps around hair follicles, most commonly on areas where the cream is applied. For some patients it’s mild and transient. For others, it’s painful enough to warrant discontinuing treatment. The frustrating part is that there’s no reliable way to predict who will develop it before they start the medication.
What Folliculitis Looks Like and Why It Gets Missed in Older Adults
Folliculitis from tapinarof usually appears within the first few weeks of treatment. It looks like small red bumps or pustules, often clustered near hair-bearing skin. In a younger patient who can describe the itching, burning, or tenderness, the connection to a new medication is fairly straightforward. But in older adults with cognitive impairment, the presentation becomes muddier. A person with Alzheimer’s disease might scratch at the affected area without being able to explain why. A caregiver might see inflamed bumps and assume it’s a bacterial skin infection, contact dermatitis from bedding, or even a reaction to a different medication. This misidentification leads to real clinical consequences.
Unnecessary courses of antibiotics are common when folliculitis gets mistaken for a staph infection. In one scenario documented in dermatology case discussions, a nursing home resident was treated with two rounds of oral antibiotics before anyone connected the skin eruption to the tapinarof cream that had been started six weeks earlier. The delay wasn’t negligence — it was a communication gap. The prescribing dermatologist had noted folliculitis as a potential side effect in the chart, but the frontline nursing staff managing daily skin checks weren’t looking for it. However, if the person with psoriasis is applying the cream to areas with little or no hair — such as the elbows or shins — folliculitis risk may be somewhat lower. The condition is fundamentally about hair follicle inflammation, so body regions with denser hair growth tend to be more affected. This distinction matters when deciding where and how to use the ointment.
Managing Psoriasis in People With Dementia — The Bigger Picture
Psoriasis affects roughly 3 percent of adults, and its prevalence doesn’t drop with age. Managing it in someone with dementia introduces challenges that go far beyond choosing the right cream. Topical medications require consistent application, usually once daily, to the correct body areas. A person in the early stages of cognitive decline might apply too much, forget to apply it, or put it on the wrong area.
By mid-stage dementia, a caregiver is almost certainly handling all medication application, which means they need to understand not just how to apply it but what to monitor. Consider the practical reality in a home care setting. A spouse caring for a partner with both moderate plaque psoriasis and Lewy body dementia is already managing multiple medications, behavioral symptoms, and likely sleep disruption. Adding a topical that requires daily application and active monitoring for a side effect that looks like a skin infection is a genuine burden. One geriatric dermatologist at Mount Sinai has noted that for patients with significant cognitive impairment, the simplest effective regimen is almost always the best one — not because simpler treatments work better pharmacologically, but because adherence and monitoring determine real-world outcomes.
How Tapinarof Compares to Other Psoriasis Treatments for Older Adults
The main alternatives to tapinarof for plaque psoriasis include topical corticosteroids, vitamin D analogs like calcipotriene, calcineurin inhibitors like tacrolimus, and for moderate-to-severe cases, systemic treatments including biologics. Each carries its own tradeoffs that become more pronounced with age and cognitive decline. Topical corticosteroids remain the most commonly prescribed first-line treatment. They work fast, are cheap, and most caregivers are familiar with them. The downside is skin atrophy with prolonged use, which is a serious concern in elderly patients whose skin is already thin and prone to tearing.
Mid-potency steroids applied for more than four weeks can cause visible skin changes. Calcipotriene avoids the atrophy problem but can cause local irritation and requires careful dosing — too much applied to too large an area can theoretically affect calcium levels. Tacrolimus works well for sensitive areas like the face and skin folds but carries a black box warning about theoretical cancer risk that makes some physicians hesitant, especially for widespread use. Tapinarof’s real advantage over all of these is its steroid-free mechanism with no skin thinning and demonstrated durability of effect — some patients in extension trials maintained clear skin for months after stopping treatment. The tradeoff is the folliculitis risk and cost. Without insurance, tapinarof can run over $1,800 for a 60-gram tube, making it functionally inaccessible for many older adults on fixed incomes unless insurance or manufacturer coupons cover it.
Warning Signs Caregivers Should Watch For
The most important thing a caregiver can do when a dementia patient starts tapinarof is document the baseline condition of the skin before treatment begins. Take photos. Note existing lesions, rashes, or irritation. This makes it far easier to identify new developments that might be folliculitis versus pre-existing psoriasis symptoms. Without a baseline, distinguishing a flare from a side effect is guesswork. Watch specifically for small red bumps or pustules in areas where the cream is applied, particularly if those areas have hair.
Also monitor for increased agitation, scratching, or resistance to dressing changes, which may be the only way a person with advanced dementia communicates that something hurts. If folliculitis develops, it does not automatically mean the medication must be stopped. Mild cases sometimes resolve on their own or respond to temporary dose reduction. But moderate-to-severe folliculitis — widespread pustules, signs of secondary infection, or significant discomfort — warrants contacting the prescriber promptly. One limitation worth noting: there are currently no published studies specifically examining tapinarof use in dementia populations. All safety and efficacy data come from clinical trials that largely excluded patients with significant cognitive impairment. Caregivers and physicians are essentially extrapolating from general adult data, which is common in geriatric medicine but means the real-world side effect profile in this population could differ.
When the Tradeoff Isn’t Worth It
For a patient with mild plaque psoriasis limited to a small area, the risk-benefit calculation of tapinarof often doesn’t favor it — especially if a low-to-mid potency steroid used intermittently has been controlling symptoms adequately. The folliculitis risk, cost, and monitoring burden make more sense when psoriasis is moderate to severe, has failed other topicals, or is located in areas where steroids are particularly risky, like the face, groin, or axillae. A 78-year-old with vascular dementia and two small psoriasis plaques on her elbows is probably better served by a familiar triamcinolone ointment applied by her aide three times a week than by introducing a new, expensive medication that requires daily application and side-effect surveillance.
What’s Ahead for Steroid-Free Psoriasis Treatment
The approval of tapinarof in 2022 signaled a broader shift in dermatology toward steroid-free topical options, and the pipeline is growing. Roflumilast cream, a PDE4 inhibitor sold as Zoryve, was approved around the same time for plaque psoriasis and has a different side effect profile — less folliculitis, but some gastrointestinal complaints. Researchers are also investigating tapinarof for atopic dermatitis, which could expand its use and generate more long-term safety data across diverse populations.
For dementia caregivers and geriatric care teams, the most useful development would be head-to-head trials comparing these newer agents specifically in older adults with comorbidities. Until those exist, treatment decisions will continue to rely on careful, individualized risk-benefit analysis — which means the caregiver’s voice in the conversation is not optional. It’s essential.
Conclusion
Tapinarof represents a genuine advance in psoriasis treatment. It avoids the skin-thinning problems of steroids, shows durable clearing effects, and offers a new option for patients who’ve exhausted older topicals. But the roughly 20 percent folliculitis rate is not a footnote — it’s a significant complication that demands active monitoring, and that monitoring becomes exponentially harder when the patient has dementia and cannot reliably report new symptoms.
Caregivers managing psoriasis in someone with cognitive impairment should have a direct conversation with the prescribing dermatologist about folliculitis risk, establish skin documentation habits before starting treatment, and know what threshold of new symptoms should trigger a call. The best psoriasis treatment is not always the newest or most targeted one. It’s the one that can be applied consistently, monitored effectively, and adjusted when something goes wrong.
Frequently Asked Questions
Can tapinarof be used on the face or sensitive skin areas?
Yes, tapinarof is approved for use on all affected areas including the face and skin folds, which is one of its advantages over potent steroids. However, folliculitis risk may be higher in areas with dense hair, such as the scalp border or jawline.
How long should you try tapinarof before deciding it isn’t working?
Clinical trials assessed results at 12 weeks. If there is no noticeable improvement by that point, the medication is unlikely to be effective for that individual. However, if severe folliculitis develops earlier, discontinuation may be warranted sooner.
Is folliculitis from tapinarof dangerous?
In most cases it’s uncomfortable but not dangerous. It typically resolves after stopping the medication or sometimes even while continuing it. The concern is when folliculitis goes unrecognized and gets treated as a bacterial infection with unnecessary antibiotics, or when it causes significant pain in a patient unable to communicate effectively.
Does tapinarof interact with dementia medications like donepezil or memantine?
No significant drug interactions have been identified between tapinarof and common dementia medications, since tapinarof works locally on the skin with minimal systemic absorption. However, always inform the prescribing physician of all current medications.
Can over-the-counter alternatives replace tapinarof for mild psoriasis?
For mild cases, OTC options like coal tar preparations, salicylic acid, and moisturizers with ceramides can provide meaningful relief. They won’t match tapinarof’s efficacy for moderate-to-severe psoriasis, but their low cost and minimal side effects make them reasonable first steps, particularly when monitoring capacity is limited.
